A study to understand the safety and effectiveness of a new drug called TAF for the treatment of long term hepatitis B infection in adolescents Part A: -To evaluate the steady state pharmacokinetics (PK) of tenofovir alafenamide (TAF) and confirm the dose of TAF 25 mg tablet given once daily in treatment-naïve and treatment-experienced adoles...

• Country None
• organs None
• Specialty None

Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from AZT containing backbone to Truvada in HIV-1-infected patients on HAART (RECOMB Study) To explore changes in limb fat assessed by DEXA measurements, after the substitution of the Zidovudine + Lamivudine NRTI-backbone by Truvada (TDF+FTC) versus maintaining the original Zidovudine-contai...

• Country None
• organs None
• Specialty None

Étude GS-US-313-1090 : étude de phase 1b évaluant la sécurité et la tolérance de l’idélalisib en monothérapie et en association avec du rituximab, de l’ifosfamide, du carboplatine et de l’étoposide (RICE) chez des enfants ayant un lymphome diffus à grandes cellules B ou un lymphome médiastinal à cellules B. Un lymphome est un cancer du système lymphatique, le principal élément du système immunitaire de l'organisme. C'est une maladie qui implique des cellules de la famille des globules blancs, appelées ly...

• Country France
• organs Lymphomes non hodgkinien
• Specialty Pédiatrie, Thérapies Ciblées, Immunothérapie - Vaccinothérapie, Chimiothérapie

A trial investigating the safety and efficacy of the drug combination Sofosbuvir/Velpatasvir/GS-9857 for 8 weeks against Sofosbuvir/Velpatasvir for 12 weeks for subjects with hepatitis C To determine the efficacy of treatment with sofosbuvir (SOF)/velpatasvir (VEL)/GS-9857 fixed dose combination (FDC) for 8 weeks and of treatment with SOF/VEL FDC for 12 weeks as measured by the propor...

• Country None
• organs None
• Specialty None

A Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 µg Regadenoson Bolus for Pharmacological Stress Echocardiography To evaluate the efficacy of a 400 µg regadenoson bolus for pharmacological stress echocardiography by comparing the stress echocardiographic images obtained after dobutamine with those obtained after ...

• Country None
• organs None
• Specialty None

GS-US-313-0125 : Essai de phase 3 randomisé, en double-aveugle, visant à évaluer l’efficacité et la tolérance de l’idélalisib associé à de la bendamustine et du rituximab, chez des patients ayant un lymphome non-hodgkinien. [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’idélalisib en association avec du rituximab et de la bendamustine, chez des patients ayant un lymphome non-hodgkinien. Les pati...

• Country France
• organs Lymphomes non hodgkinien
• Specialty Thérapies Ciblées

A trial looking at the treatment of SOF/GS-5816 for 12 weeks in patients with hepatitis C infection The primary objectives of this study are: - To evaluate the efficacy of treatment with SOF/GS-5816 for 12 weeks in subjects with chronic HCV infection as measured by the proportion of subjects wit...

• Country None
• organs None
• Specialty None

GS-US-313-0124 : Essai de phase 3 randomisé, en double-aveugle, visant à évaluer l’efficacité et la tolérance de l’idélalisib associé au rituximab, chez des patients ayant un lymphome non-hodgkinien. [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’idélalisib en association avec du rituximab, chez des patients ayant un lymphome non-hodgkinien. Les patients seront répartis d...

• Country France
• organs Lymphomes non hodgkinien
• Specialty Thérapies Ciblées

A study looking at 12 weeks treatment with GS-7977 + Ribavirin for patients with chronic genotype 2 or 3 Hepatitis C infection who previously took part in Gilead-sponsored GS-7977 studies in the control arms The primary objectives of this study are: • To determine the efficacy of GS-7977 + RBV as measured by the proportion of subjects with sustained viral response at 12 weeks after discontinuation of the...

• Country None
• organs None
• Specialty None

A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) Estudio para evaluar la seguridad y la eficacia de selonsertib en pacientes con cirrosis compensada debida a esteatohepatitis no alcohólica (EHNA) The primary objective of this study is: To evaluate whether SEL can cause fibrosis regression and reduce associated complications in subjects with cirrhosis due to NASH. Objetivo principal: Eval...

• Country None
• organs None
• Specialty None